{
  "docId": "019de075-c1ce-7016-922a-ee59c26b52e2",
  "docSlug": "7a9033616f2f52a3ff84a89721dd4a41",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 23,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/14",
  "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2",
  "deckJsonHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2.json",
  "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.95,
        "x": 0.03,
        "y": 0.225
      },
      "kind": "list",
      "text": "Precision Medicine Approach: Discovered at the University of Edinburgh, Scotland; A potent, novel, small molecule inhibitor of YES1/SRC signaling; YES1-Hippo pathway alteration associated with sensitivity to NXP900 in squamous cell models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "855f34e9-33fe-4ef0-a7a0-7ac434a99977",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.95,
        "x": 0.03,
        "y": 0.415
      },
      "kind": "list",
      "text": "Differentiated Features: Highly selective - Lack of immunosuppression; Unique mechanism of action - Complete shut-down of the SRC pathway by scaffold and catalytic domain inactivation; Ability to cross the blood-brain-barrier",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92723363-f5d6-42f0-adcb-402e6e7d5faa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.95,
        "x": 0.03,
        "y": 0.605
      },
      "kind": "list",
      "text": "Strong Preclinical Proof of Concept: POC in multiple xenograft models – significant single-agent activity in squamous cell cancer models; Ability to re-sensitize resistant NSCLC cells to osimertinib (2022 paper); Ability to reverse resistance to enzalutamide in mCRPC (2023 paper)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "987e1190-ccad-4d4d-9f9a-64ca2c052fbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.795
      },
      "kind": "list",
      "text": "Phase 1 Program: IND cleared; Phase 1a clinical trial expected to begin in 3Q2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7e48e38-aea6-4d00-891b-3f4f8914afd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.43,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "NXP900 Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "802a684d-6e8d-43be-b3a6-bf2f7cee319f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "24969a1d-6317-4438-83a6-6522029d833f",
      "evidence": "list/bullet: Strong Preclinical Proof of Concept: POC in multiple xenograft models – significant single-agent activity in squamous cell cancer models; Ability to re-sensitize resistant NSCLC cells to osimertinib (2022 pa",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 20,
      "from": 12,
      "beatId": "8122ef7d-2234-47f6-ba29-f1f7415cb0cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The document presents a roadmap for NXP800 and NXP900",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb",
      "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline",
      "position": 0,
      "objective": "Highlight the cost of inaction in oncology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac",
      "evidence": "The document presents data on the potential of NXP800 and NXP900",
      "position": 1,
      "objective": "Present Nuvectis Pharma's solution as a quick win and big bet",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}